Topic: Allergan Inc.

Allergan to pay $600 million to settle off-label marketing charges

Modern Medicine - 513 days ago
Allergan's recently announced $600 million settlement to resolve federal charges that it marketed Botox (onabotulinumtoxinA) for unapproved uses could hinder innovation and hamper patient care, some dermatologists worry. Under terms of the settlement with the Justice Department, announced Sept. 1, Allergan will ...

Allergan CEO defends Botox from new challenger

AP Features - 1019 days ago
Botox, the refined form of the botulism-causing toxin that temporarily removes frown lines.Barely a week after the Food and Drug Administration cleared way for a second anti-wrinkle drug, Botox maker Allergan is defending its top product as it also fights against an ...
Read More...

Bimatoprost gets nod as hypotrichosis treatment

Modern Medicine - 1139 days ago
Irvine, CA-Allergan has received FDA approval for its 0.03% bimatoprost ophthalmic solution (Latisse) as a novel treatment for hypotrichosis of the eyelashes. "[The new product] fulfills a significant and previously unmet need in the medical aesthetic marketplace with a product approved by ...